What Is Parkinson's Disease?

Parkinson's disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons in a brain region called the substantia nigra. This loss disrupts the signaling pathways that control movement, leading to the hallmark symptoms of tremor, bradykinesia (slowness of movement), rigidity, and postural instability. Parkinson's also causes a wide range of non-motor symptoms — including depression, cognitive changes, sleep disturbances, and constipation — that often precede motor symptoms by years.

Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease and the fastest-growing neurological condition in the world. Nearly 90,000 Americans are diagnosed each year, and an estimated one million people in the United States and more than eleven million worldwide are living with the disease. The average age of diagnosis is around 60, though 5 to 10 percent of cases are classified as young-onset Parkinson's, meaning symptoms begin before age 50. Men are approximately 1.5 times more likely to develop the disease than women.

How Parkinson's Disease Affects the Brain

The substantia nigra is a small, dark-pigmented structure deep within the midbrain. It is part of the basal ganglia, a group of brain structures responsible for initiating and fine-tuning voluntary movement. In a healthy brain, dopamine-producing neurons in the substantia nigra send signals to the striatum, another basal ganglia structure, which relays motor instructions through a complex circuit of excitatory and inhibitory pathways to the muscles.

In Parkinson's disease, approximately 50 to 80 percent of these dopamine-producing neurons have already degenerated by the time motor symptoms first appear. This means the disease process begins years — sometimes a decade or more — before a person notices anything wrong. The remaining neurons initially compensate by increasing dopamine output, but eventually the system can no longer keep up, and motor symptoms emerge.

Dopamine depletion causes disinhibition of striatal neurons, producing the movement abnormalities that characterize the disease. However, the neurodegeneration in Parkinson's extends well beyond the dopaminergic system. Noradrenergic, serotonergic, and cholinergic neurons are also affected, which accounts for the broad spectrum of non-motor symptoms that are now understood to be integral to the disease rather than secondary complications.

Alpha-Synuclein and Lewy Body Pathology

At the cellular level, a defining feature of Parkinson's disease is the abnormal accumulation of the protein alpha-synuclein inside affected neurons. Alpha-synuclein is a naturally occurring protein that plays a role in synaptic function and neurotransmitter release. In Parkinson's disease, this protein misfolds and aggregates into insoluble clumps called Lewy bodies and thread-like structures called Lewy neurites.

These aggregates are found throughout the brains of people with Parkinson's disease and are considered the pathological hallmark of the condition. Research has shown that misfolded alpha-synuclein displays prion-like properties — it can spread from cell to cell in a predictable pattern through the nervous system. This concept is central to the Braak staging hypothesis, proposed by German neuropathologist Heiko Braak in 2003, which suggests that alpha-synuclein pathology may begin in the peripheral nervous system (the gut and olfactory bulb) and progressively ascend to the brainstem, midbrain, and eventually the cortex over years to decades.

Toxic alpha-synuclein aggregates disrupt cellular function through multiple mechanisms: mitochondrial dysfunction, oxidative stress, lysosomal impairment, endoplasmic reticulum stress, and neuroinflammation. Post-translational modifications of the protein — particularly phosphorylation at serine-129 — influence its tendency to aggregate and its toxicity. The alpha-synuclein seed amplification assay (SAA), which can detect misfolded alpha-synuclein in cerebrospinal fluid, is emerging as a potentially transformative diagnostic and research tool.

The NSD-ISS Biological Definition (2023)

Historically, Parkinson's disease has been defined by its clinical symptoms — a person must show specific motor signs to receive a diagnosis. In 2023, a landmark proposal by the Movement Disorder Society and collaborating researchers introduced a new framework: the Neuronal Synuclein Disease Integrated Staging System (NSD-ISS). This system proposes a biological definition of Parkinson's disease based on the presence of pathological alpha-synuclein (detected by biomarkers such as the CSF seed amplification assay) combined with evidence of neurodegeneration — regardless of whether clinical symptoms have appeared.

Under the NSD-ISS, the disease is staged from 0 (biomarker-positive but no symptoms) through 6 (severe disability), bridging the gap between the presymptomatic biological process and the clinical disease. This reconceptualization has important implications for research: it could enable clinical trials to enroll people in the earliest stages of the disease, when neuroprotective interventions may be most effective. The NSD-ISS is not yet used in routine clinical practice, but it represents a major shift in how the scientific community understands and classifies Parkinson's disease.

Core Motor Symptoms

Parkinson's disease is clinically defined by four cardinal motor symptoms. Not every person experiences all four, and they often develop asymmetrically — typically beginning on one side of the body before gradually affecting both sides over months to years.

• Tremor. A rhythmic, involuntary shaking that usually begins in one hand or arm, often described as a “pill-rolling” tremor because the thumb and index finger move as if rolling a small object. Resting tremor — occurring when the hand is relaxed — is the most recognizable symptom, present in about 70 percent of people with PD at diagnosis. Not all tremor is Parkinson's: essential tremor, the most common movement disorder, is distinct and typically worsens with action rather than rest.
• Bradykinesia (slowness of movement). Considered the most disabling motor symptom, bradykinesia makes everyday tasks like buttoning a shirt, writing, or rising from a chair increasingly difficult. Movements become smaller and slower over time. Bradykinesia is a required feature for a clinical diagnosis of Parkinson's disease under the 2015 MDS diagnostic criteria.
• Rigidity. Muscles become stiff and resist passive movement. This can cause pain and limit range of motion. Doctors may detect “cogwheel rigidity,” a ratchet-like resistance felt when moving a patient's limb, caused by the combination of rigidity and underlying tremor.
• Postural instability. Impaired balance and coordination develop later in the disease course and significantly increase fall risk. People may lean forward (propulsion) or backward (retropulsion) and have trouble making quick postural corrections. Postural instability is generally not present in early-stage Parkinson's disease; its early appearance may suggest an alternative diagnosis.

Non-Motor Symptoms

Parkinson's disease is now understood as a multisystem disorder, not solely a movement disease. Non-motor symptoms affect virtually all people with PD at some point and are increasingly recognized as a major driver of reduced quality of life — in many studies, more so than the motor symptoms themselves. Non-motor symptoms can appear years before motor symptoms and are part of the disease process, not merely reactions to diagnosis.

• Loss of smell (anosmia or hyposmia). A diminished sense of smell is one of the earliest signs, sometimes appearing 5 to 10 years before motor symptoms. It is present in an estimated 90 percent of people with Parkinson's disease.
• Sleep disturbances. REM sleep behavior disorder (RBD), insomnia, excessive daytime sleepiness, and restless legs syndrome are common. RBD — in which a person physically acts out vivid dreams — is the single strongest prodromal predictor of future Parkinson's diagnosis. Sleep disorders affect up to 80 percent of patients within 5 years of diagnosis.
• Constipation and gastrointestinal dysfunction. Slowed gut motility is extremely prevalent, affecting up to two-thirds of people with PD, and may appear years before diagnosis. The enteric nervous system is among the earliest structures affected by alpha-synuclein pathology.
• Depression and anxiety. Depression affects approximately 40 percent of people with Parkinson's, and anxiety is similarly common. These result from neurochemical changes in serotonin, norepinephrine, and dopamine pathways — they are part of the disease itself, not simply emotional reactions.
• Cognitive changes. Approximately 24 to 31 percent of people with PD develop dementia over the course of the disease, and a significant additional proportion experience mild cognitive impairment. Cognitive decline tends to become more prominent in later stages.
• Autonomic dysfunction. Orthostatic hypotension (drops in blood pressure upon standing), urinary urgency or incontinence, excessive sweating, and sexual dysfunction can all occur as the autonomic nervous system is progressively affected.
• Pain. Pain affects more than two-thirds of people with Parkinson's and can take multiple forms: musculoskeletal pain from rigidity, neuropathic pain, dystonic pain from involuntary muscle contractions, and central pain syndromes.

Parkinson's Disease vs. Other Conditions

Several conditions share features with Parkinson's disease and can be confused with it, particularly in early stages. Understanding the key differences is important for accurate diagnosis and appropriate treatment.

Who Gets Parkinson's Disease?

Parkinson's disease affects people of all backgrounds, but certain patterns are well documented. The average age of onset is around 60, and risk increases steeply with each decade of life. Approximately 1 percent of people over 60 and 3 to 4 percent of those over 80 are affected. About 5 to 10 percent of cases are classified as young-onset Parkinson's (diagnosis before age 50), and in rare cases diagnosis occurs before age 40.

Men are roughly 1.5 times more likely to develop the disease than women, a disparity attributed to a combination of hormonal factors (estrogen may be neuroprotective), differences in environmental exposure, and possible genetic interactions. In the United States, nearly 90,000 people are newly diagnosed each year — approximately 50 percent higher than prior estimates, reflecting improved study methodologies. Worldwide, the figure exceeds eleven million and is rising. Between 1990 and 2019, the global prevalence of Parkinson's more than doubled, prompting researchers to describe a “Parkinson pandemic” driven by population aging, increasing environmental exposures, and longer survival.

How Is Parkinson's Disease Diagnosed?

There is no single blood test or brain scan that definitively confirms Parkinson's disease. Diagnosis is made clinically — based on a detailed neurological examination, medical history, symptom pattern, and response to Parkinson's medications — ideally by a movement disorder specialist. The 2015 MDS Clinical Diagnostic Criteria require the presence of bradykinesia plus at least one additional motor sign (resting tremor, rigidity, or both), along with supportive features and the absence of exclusion criteria and red flags.

Imaging tests such as DaTscan (which visualizes dopamine transporter levels) can support the diagnosis by distinguishing Parkinson's from conditions that mimic it, such as essential tremor or drug-induced parkinsonism. MRI scans are used to rule out structural causes. The alpha-synuclein seed amplification assay (SAA), while not yet in routine clinical use, has shown high sensitivity and specificity in research settings and may become a standard diagnostic tool in the future.

Current Treatments

There is currently no cure for Parkinson's disease, and no treatment has been proven to slow or stop the underlying neurodegeneration. However, a range of therapies can effectively manage symptoms and maintain quality of life, often for many years.

• Levodopa/carbidopa. Levodopa, combined with carbidopa to prevent peripheral side effects, remains the gold standard medication for motor symptoms. It is the most effective treatment available and provides clear symptomatic benefit in most patients. The American Academy of Neurology's 2021 practice guideline concluded that levodopa provides superior motor symptom improvement compared to dopamine agonists and MAO-B inhibitors.
• Dopamine agonists. Pramipexole, ropinirole, and rotigotine mimic dopamine's effects. They may be used as initial therapy in younger patients or as adjuncts to levodopa. Side effects include impulse control disorders, hallucinations, and excessive daytime sleepiness.
• MAO-B inhibitors. Selegiline, rasagiline, and safinamide slow the breakdown of dopamine in the brain. Often used in early disease or as adjunctive therapy.
• COMT inhibitors. Entacapone, opicapone, and tolcapone extend the duration of levodopa's effect. Used to reduce motor fluctuations (“off” time).
• Deep brain stimulation (DBS). A surgically implanted device delivers electrical impulses to specific brain targets (subthalamic nucleus or globus pallidus internus). DBS can significantly reduce motor fluctuations and dyskinesia in carefully selected patients. Five-year outcome data published in 2025 showed sustained motor improvements.
• MR-guided focused ultrasound. A noninvasive procedure that uses focused sound waves to create targeted lesions in specific brain regions. FDA-approved for tremor-dominant PD and expanded indications.
• Physical therapy and exercise. Regular exercise is one of the most impactful interventions available. A 2023 Cochrane review of 156 randomized controlled trials found small-to-large effects across multiple exercise types on motor function and quality of life. High-intensity aerobic exercise, resistance training, tai chi, boxing, and dance have all shown benefits.

Disease-Modifying Research

The most intensely pursued goal in Parkinson's research is the development of disease-modifying therapies — treatments that could slow, halt, or reverse the underlying neurodegeneration rather than simply managing symptoms. Multiple approaches are in clinical trials:

• Alpha-synuclein immunotherapy. Monoclonal antibodies designed to clear toxic alpha-synuclein from the brain. Prasinezumab, the most advanced candidate, entered Phase 3 trials in November 2025 after showing trends toward slower motor progression in Phase 2 studies.
• GLP-1 receptor agonists. Diabetes medications like lixisenatide and exenatide are being investigated for possible neuroprotective effects. Results are mixed: lixisenatide showed modest benefit in a Phase 2 trial, but exenatide failed to show significant efficacy in Phase 3. Larger trials are needed, and the Parkinson's Foundation explicitly warns against using these drugs off-label for PD outside of clinical trials.
• Gene therapy. Several trials are testing viral vector delivery of neuroprotective genes (GDNF, AADC) directly to the brain. AB-1005 (GDNF gene therapy) received FDA Regenerative Medicine Advanced Therapy designation in February 2025.
• Stem cell therapy. Bemdaneprocel, the first large-scale stem cell therapy for PD, entered Phase 3 trials in September 2025. The therapy involves implanting dopamine-producing neurons derived from stem cells directly into the brain.

While no disease-modifying treatment has yet been proven effective, the pace and scope of research are greater than at any point in history, and the biological understanding of the disease has advanced enormously in recent years.

Living with Parkinson's Disease

A Parkinson's diagnosis is life-changing, but it is not a death sentence. Many people live full, active lives for years and even decades after diagnosis. Average life expectancy after diagnosis exceeds 14 years, and many individuals live 20 to 30 years with appropriate management. A comprehensive approach — combining optimized medication, regular vigorous exercise, physical and occupational therapy, mental health support, good nutrition, and a strong care team — makes a meaningful difference in day-to-day quality of life.

Organizations such as the Parkinson's Foundation (Helpline: 1-800-4PD-INFO / 1-800-473-4636) and the Michael J. Fox Foundation provide extensive resources, support groups, and community connections. Engaging with these resources, maintaining social connections, and working with a multidisciplinary care team are associated with better outcomes and improved quality of life at every stage of the disease.